COMP <GO>
SYRE vs BMRN // OPERATING MARGIN
Spyre Therapeutics Inc. (NASDAQ) VS. BioMarin Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: SYRE 4
— BMRN 5
■ METRIC PARITY
LAST: $95.51 (-1.09%) • MKT CAP: $9.97B
operating-margins
—
LAST: $57.44 (-1.83%) • MKT CAP: $11.12B
operating-margins
12.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. BMRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | BMRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 77.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 6.00% | -26.00 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 6.51% | -8.15 | BMRN | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | 12.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 10.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 12.90% | +4.70 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.57 | +20.43 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.4 | 49.5 | +5.90 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.95 | -0.06 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.8x | -4.80 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $11.12B | -$1.15B | BMRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | BMRN REV | SYRE GROSS % | BMRN GROSS % | SYRE FCF | BMRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $586.8M | $3.22B | — | 77.7% | -$169.3M | $725.0M |
| FY 2024 | $584.0M | $2.85B | — | 79.7% | -$157.4M | $487.4M |
| FY 2023 | $886.0K | $2.42B | — | — | -$99.9M | $50.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
BMRN // BETA 0.95